动物造模,自身免疫性脑脊髓炎 z-bio 2023-02-28 400

　　Objective: To investigate the effect of vasoactive intestinal peptide regulating the balance of CD4+CD25+Treg/Th17 on the prevention and treatment of experimental autoimmune encephalomyelitis.

　　Methods: 60 healthy female wistar rats were randomly divided into normal control group, EAE control group, VIP low-dose control group and VIP high-dose control group. EAE model was established by induction of myelin basic protein (MBP) + complete Freund's adjuvant (CFA). From the day of modeling, VIP 4 nmol/kg (0.2 mL) and 16 nmol/kg (0.8 mL) were intraperitoneally injected into the VIP low-dose and high-dose prevention and control groups every other day, and the normal control group and EAE control group were injected with VIP. 0.8 mL of normal saline for 10 consecutive days. The incidence of rats was observed; the basic pathological changes of brain tissue were observed by HE staining; the proportion of CD4+CD25+Treg and Th17 cells in spleen tissue was detected by flow cytometry; the changes of TGF-β1 and IL-17A factors in brain tissue were detected by ELISA.

　　Results: Compared with the EAE control group, the onset latency period was prolonged, the progression period was shortened, and the neurological dysfunction score (NDS) at the peak of the onset was decreased in the VIP prevention and treatment groups. HE staining showed that no inflammatory cells were found in the brain tissue of the normal control group. Compared with the EAE group, the infiltration degree of inflammatory cells in the brain tissue of the rats in the VIP groups was significantly decreased; compared with the EAE control group, the proportion of CD4+CD25+Treg cell subsets in the spleen tissue of the VIP groups increased, and Th17 The proportion of cell subsets decreased, and there was a certain dose-effect relationship among the groups; the content of TGF-β1 in the brain tissue of the rats in each dose group of VIP was significantly higher than that of the EAE group, and the content of IL-17A was significantly lower than that of the EAE group. There is a dose-dependent relationship between them.

　　Conclusion: VIP can increase the proportion of CD4+CD25+Treg cells, promote the secretion of TGF-β1 factor, down-regulate the proportion of Th17 cells, and inhibit the expression of IL-17A factor, thereby reducing the infiltration degree of inflammatory cells in brain tissue and exerting a preventive effect on EAE.